Interactions between human immunodeficiency virus type 1 and vaccinia virus in human lymphoid tissue ex vivo

Journal of Virology

Volumn 81, Issue 22, 2007, Pages 12458-12464

  Vanpouille, Christophe ^a,b,c   Biancotto, Angélique ^a   Lisco, Andrea ^a   Brichacek, Beda ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VIRUS VECTOR; VIRUS VACCINE; VIRUS VECTOR;

ARTICLE; BIOLOGICAL WARFARE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EVALUATION RESEARCH; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; LYMPHOID TISSUE; PRIORITY JOURNAL; SMALLPOX; T LYMPHOCYTE ACTIVATION; TONSIL; VACCINIA VIRUS; VIRUS PATHOGENESIS; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CXC; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; RECEPTORS, CCR5; T-LYMPHOCYTES; TONSIL; VACCINIA VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 36048952821     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00326-07     Document Type: Article

References (36)

1. Alonso, J. M., J. Rodriguez, E. Vinuela, G. Kroemer, and C. Martinez. 1991. Highly efficient expression of proteins encoded by recombinant vaccinia virus in lymphocytes. Scand. J. Immunol. 34:619-626.
2. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
3. Breman, J. G., and D. A. Henderson. 2002. Diagnosis and management of smallpox. N. Engl. J. Med. 346:1300-1308.
4. Broccolo, F., G. Locatelli, L. Sarmati, S. Piergiovanni, F. Veglia, M. Andreoni, S. Butto, B. Ensoli, P. Lusso, and M. S. Malnati. 2002. Calibrated real-time PCR assay for quantitation of human herpesvirus 8 DNA in biological fluids. J. Clin. Microbiol. 40:4652-4658.
5. Bursill, C. A., J. L. Cash, K. M. Channon, and D. R. Greaves. 2006. Membrane-bound CC chemokine inhibitor 35K provides localized inhibition of CC chemokine activity in vitro and in vivo. J. Immunol. 177:5567-5573.
6. Bursill, C. A., R. P. Choudhury, Z. Ali, D. R. Greaves, and K. M. Channon. 2004. Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation 110:2460-2466.
7. Carfi, A., C. A. Smith, P. J. Smolak, J. McGrew, and D. C. Wiley. 1999. Structure of a soluble secreted chemokine inhibitor vCCl (p35) from cowpox virus. Proc. Natl. Acad. Sci. USA 96:12379-12383.
8. Chahroudi, A., R. Chavan, N. Kozyr, E. K. Waller, G. Silvestri, and M. B. Feinberg. 2005. Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J. Virol. 79:10397-10407.
9. Condack, C., J. C. Grivel, P. Devaux, L. Margolis, and R. Cattaneo. 2007. Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration. J. Infect. Dis. 196:541-549.
10. Drexler, I., C. Staib, and G. Sutter. 2004. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr. Opin. Biotechnol. 15:506-512.
11. Earl, P. L., J. L. Americo, L. S. Wyatt, L. A. Eller, J. C. Whitbeck, G. H. Cohen, R. J. Eisenberg, C. J. Hartmann, D. L. Jackson, D. A. Kulesh, M. J. Martinez, D. M. Miller, E. M. Mucker, J. D. Shamblin, S. H. Zwiers, J. W. Huggins, P. B. Jahrling, and B. Moss. 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182-185.
12. Glushakova, S., B. Baibakov, L. B. Margolis, and J. Zimmerberg. 1995. Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat. Med. 1:1320-1322.
13. Glushakova, S., J. C. Grivel, W. Fitzgerald, A. Sylwester, J. Zimmerberg, and L. B. Margolis. 1998. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat. Med. 4:346-349.
14. Grivel, J. C., M. Garcia, W. J. Moss, and L. B. Margolis. 2005. Inhibition of HIV-1 replication in human lymphoid tissues ex vivo by measles virus. J. Infect. Dis. 192:71-78.
15. Grivel, J. C., Y. Ito, G. Faga, K. Santoro, F. Shaheen, M. S. Malnati, W. Fitzgerald, P. Lusso, and L. Margolis. 2001. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat. Med. 7:1232-1235.
16. + T cells in ex vivo-infected human lymphoid tissue. J. Virol. 74:8077-8084.
17. Grivel, J. C., and L. B. Margolis. 1999. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nat. Med. 5:344-346.
18. Grivel, J. C., F. Santoro, S. Chen, G. Faga, M. S. Malnati, Y. Ito, L. Margolis, and P. Lusso. 2003. Pathogenic effects of human herpesvirus 6 in human lymphoid tissue ex vivo. J. Virol. 77:8280-8289.
19. Guillaume, J. C., P. Saiag, J. Wechsler, M. C. Lescs, and J. C. Roujeau. 1991. Vaccinia from recombinant virus expressing HIV genes. Lancet 337:1034-1035.
20. Honczarenko, M., Y. Le, A. M. Glodek, M. Majka, J. J. Campbell, M. Z. Ratajczak, and L. E. Silberstein. 2002. CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor. Blood 100:2321-2329.
21. Karlsson, I., J. C. Grivel, S. S. Chen, A. Karlsson, J. Albert, E. M. Fenyo, and L. B. Margolis. 2005. Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue. J. Virol. 79:11151-11160.
22. Lisco, A., J. C. Grivel, A. Biancotto, C. Vanpouille, F. Origgi, M. S. Malnati, D. Schols, P. Lusso, and L. B. Margolis. 2007. Viral interactions in human lymphoid tissue: human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J. Virol. 81:708-717.
23. + T cells in multiple tissues during acute SIV infection. Nature 434:1093-1097.
24. Moss, B. 2001. Poxviridae: the viruses and their replication, p. 2849-2883. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed. Lippincott-Raven Publishers, Philadelphia, PA.
25. Moss, B. 2006. Poxvirus entry and membrane fusion. Virology 344:48-54.
26. Olson, V. A., T. Laue, M. T. Laker, I. V. Babkin, C. Drosten, S. N. Shchelkunov, M. Niedrig, I. K. Damon, and H. Meyer. 2004. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. J. Clin. Microbiol. 42:1940-1946.
27. Picard, O., J. Lebas, J. C. Imbert, P. Bigel, and D. Zagury. 1991. Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals. J. Acquir. Immune Defic. Syndr. 4:641-643.
28. Rahbar, R., T. T. Murooka, A. A. Hinek, C. L. Galligan, A. Sassano, C. Yu, K. Srivastava, L. C. Platanias, and E. N. Fish. 2006. Vaccinia virus activation of CCR5 invokes tyrosine phosphorylation signaling events that support virus replication. J. Virol. 80:7245-7259.
29. Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
30. Robinson, H. L. 2003. Prime boost vaccines power up in people. Nat. Med. 9:642-643.
31. Sanchez-Puig, J. M., L. Sanchez, G. Roy, and R. Blasco. 2004. Susceptibility of different leukocyte cell types to vaccinia virus infection. Virol. J. 1:10.
32. Seet, B. T., J. B. Johnston, C. R. Brunetti, J. W. Barrett, H. Everett, C. Cameron, J. Sypula, S. H. Nazarian, A. Lucas, and G. McFadden. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
33. Smith, C. A., T. D. Smith, P. J. Smolak, D. Friend, H. Hagen, M. Gerhart, L. Park, D. J. Pickup, D. Torrance, K. Mohler, K. Schooley, and R. G. Goodwin. 1997. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 236:316-327.
34. Vanderplasschen, A., M. Hollinshead, and G. L. Smith. 1998. Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J. Gen. Virol. 79:877-887.
35. Xiang, J., S. L. George, S. Wunschmann, Q. Chang, D. Klinzman, and J. T. Stapleton. 2004. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1α, MIP-1β, and SDF-1. Lancet 363:2040-2046.
36. Yu, Q., B. Jones, N. Hu, H. Chang, S. Ahmad, J. Liu, M. Parrington, and M. Ostrowski. 2006. Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. Vaccine 24:6376-6391.